文献速递物质与行为成瘾

每周一次司美格鲁肽治疗成人酒精使用障碍:一项随机临床试验

Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2025-01-01

这项2期双盲随机平行组试验在美国一家学术医疗中心纳入48名非治疗寻求的酒精使用障碍成人,比较每周皮下注射司美格鲁肽与安慰剂9周的效果。司美格鲁肽降低了治疗后实验室酒精自我给药任务的饮酒量(克数β=-0.48,P=0.01)和呼气酒精峰值浓度(β=-0.46,P=0.03),并减少每次饮酒日饮酒量、每周渴求,预测重饮酒随时间更大程度减少。

要点

  • 司美格鲁肽降低实验室自我给药任务的饮酒克数(β=-0.48,P=0.01)和呼气酒精峰值浓度(β=-0.46,P=0.03)。
  • 司美格鲁肽未影响每日平均饮酒量或饮酒天数,但减少每次饮酒日饮酒量(β=-0.41,P=0.04)和每周酒精渴求(β=-0.39,P=0.01)。
  • 司美格鲁肽预测重饮酒随时间更大程度减少(β=0.84,P=0.04),并在当前吸烟亚组中预测每日吸烟支数相对更大减少(β=-0.10,P=0.005)。

核心结论

  • 这些发现提供初步前瞻性证据,表明低剂量司美格鲁肽可减少渴求和部分饮酒结局,支持开展更大规模临床试验评估GLP-1RAs治疗酒精使用障碍。

研究设计与样本

  • 这项2期双盲随机平行组试验涉及9周门诊治疗,在美国一家学术医疗中心于2022年9月至2024年2月入组。
  • 评估504名潜在参与者后,随机分配48名非治疗寻求的酒精使用障碍参与者。
  • 参与者每周门诊访视接受司美格鲁肽(每周0.25 mg用4周、每周0.5 mg用4周、1.0 mg用1周)或安慰剂。

主要发现

  • 48名参与者(34名[71%]女性;平均[SD]年龄39.9[10.6]岁)被随机分配。
  • 低剂量司美格鲁肽减少治疗后实验室自我给药任务的饮酒量,饮酒克数β=-0.48(95%CI -0.85至-0.11;P=0.01),呼气酒精峰值浓度β=-0.46(95%CI -0.87至-0.06;P=0.03),效应量为中到大。
  • 司美格鲁肽未影响每日平均饮酒量或饮酒天数,但显著减少每次饮酒日饮酒量(β=-0.41;95%CI -0.73至-0.09;P=0.04)和每周酒精渴求(β=-0.39;95%CI -0.73至-0.06;P=0.01)。
  • 司美格鲁肽相对安慰剂预测重饮酒随时间更大程度减少(β=0.84;95%CI 0.71至0.99;P=0.04)。
  • 显著的治疗×时间交互作用表明,司美格鲁肽治疗在当前吸烟个体亚组中预测每日吸烟支数相对更大减少(β=-0.10;95%CI -0.16至-0.03;P=0.005)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Preclinical, observational, and pharmacoepidemiology evidence indicates that glucagon-like peptide 1 receptor agonists (GLP-1RAs) may reduce alcohol intake. Randomized trials are needed to determine the clinical significance of these findings. OBJECTIVE: To evaluate the effects of once-weekly subcutaneous semaglutide on alcohol consumption and craving in adults with alcohol use disorder (AUD). DESIGN, SETTING, AND PARTICIPANTS: This was a phase 2, double-blind, randomized, parallel-arm trial involving 9 weeks of outpatient treatment. Enrollment occurred at an academic medical center in the US from September 2022 to February 2024. Of 504 potential participants assessed, 48 non-treatment-seeking participants with AUD were randomized. INTERVENTION: Participants received semaglutide (0.25 mg/week for 4 weeks, 0.5 mg/week for 4 weeks, and 1.0 mg for 1 week) or placebo at weekly clinic visits. MAIN OUTCOMES AND MEASURES: The primary outcome was laboratory alcohol self-administration, measured at pretreatment and posttreatment (0.5 mg/week). Secondary and exploratory outcomes, including prospective changes in alcohol consumption and craving, were assessed at outpatient visits. RESULTS: Forty-eight participants (34 [71%] female; mean [SD] age, 39.9 [10.6] years) were randomized. Low-dose semaglutide reduced the amount of alcohol consumed during a posttreatment laboratory self-administration task, with evidence of medium to large effect sizes for grams of alcohol consumed (β, -0.48; 95% CI, -0.85 to -0.11; P = .01) and peak breath alcohol concentration (β, -0.46; 95% CI, -0.87 to -0.06; P = .03). Semaglutide treatment did not affect average drinks per calendar day or number of drinking days, but significantly reduced drinks per drinking day (β, -0.41; 95% CI, -0.73 to -0.09; P = .04) and weekly alcohol craving (β, -0.39; 95% CI, -0.73 to -0.06; P = .01), also predicting greater reductions in heavy drinking over time relative to placebo (β, 0.84; 95% CI, 0.71 to 0.99; P = .04). A significant treatment-by-time interaction indicated that semaglutide treatment predicted greater relative reductions in cigarettes per day in a subsample of individuals with current cigarette use (β, -0.10; 95% CI, -0.16 to -0.03; P = .005). CONCLUSIONS AND RELEVANCE: These findings provide initial prospective evidence that low-dose semaglutide can reduce craving and some drinking outcomes, justifying larger clinical trials to evaluate GLP-1RAs for alcohol use disorder. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05520775.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025. PMID: 39937469. doi:10.1001/jamapsychiatry.2024.4789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。